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All known benzoisochromanequinone (BIQ) biosyn-
thetic gene clusters carry a set of genes encoding
a two-component monooxygenase homologous to
the ActVA-ORF5/ActVB system for actinorhodin
biosynthesis in Streptomyces coelicolor A3(2).
Here, we conductedmolecular genetic and biochem-
ical studies of this enzyme system. Inactivation of
actVA-ORF5 yielded a shunt product, actinoperylone
(ACPL), apparently derived from 6-deoxy-dihydro-
kalafungin. Similarly, deletion of actVB resulted in
accumulation of ACPL, indicating a critical role for
the monooxygenase system in C-6 oxygenation,
a biosynthetic step common to all BIQ biosyntheses.
Furthermore, in vitro, we showed a quinone-forming
activity of the ActVA-ORF5/ActVB system in addition
to that of a known C-6 monooxygenase, ActVA-
ORF6, by using emodinanthrone as a model
substrate. Our results demonstrate that the act
gene cluster encodes two alternative routes for
quinone formation by C-6 oxygenation in BIQ biosyn-
thesis.
INTRODUCTION
Bacteria of the genus Streptomyces are one of the most impor-
tant groups of microorganisms in producing a huge variety of
secondary metabolites, including antibiotics (Chater and Hop-
wood, 1993). Actinorhodin (ACT) 1 is a blue-pigmented antibiotic
produced by Streptomyces coelicolor A3(2), which is genetically
the most-characterized actinomycete (Bentley et al., 2002). ACT
belongs to a class of aromatic polyketides, the benzoisochroma-
nequinone (BIQ) antibiotics. Historically, ACT 1 is the first antibi-
otic whose whole biosynthetic gene cluster was cloned and has
served as one of the best model compounds for studying type II
polyketide synthase (PKS), their ancillary enzymes, and subse-
quent post-PKS tailoring enzymes. Consequently, numerous
studies have provided much important information on ACT
biosynthesis. Recent advances in understanding the funda-
mental processes revealed mechanistic details of the assembly
of the basic carbon skeleton accomplished by the type II minimal226 Chemistry & Biology 16, 226–236, February 27, 2009 ª2009 ElsPKS (Beltran-Alvarez et al., 2007); conversion of the octaketide
to the bicyclic intermediate 2 catalyzed by the ketoreductase
(KR) for the C-9 position (Korman et al., 2008); and the stereo-
specific ketoreduction at C-3, leading to the first chiral biosyn-
thetic intermediate, 4-dihydro-9-hydroxy-1-methyl-10-oxo-3-
H-naptho-[2,3-c]-pyran-3-(S)-acetic acid, (S)-DNPA 3 (Itoh
et al., 2007). Subsequent oxygenation at the C-6 position
(Figure 1A) is the key step to complete BIQ chromophore
synthesis, and biochemical (Kendrew et al., 1997) and crystallo-
graphic (Sciara et al., 2003) studies showed that the ActVA-
ORF6 protein functions as a C-6monooxygenase, which, unusu-
ally, requires no prosthetic group, metal ion, or cofactor. At
present, however, there is no in vivo evidence for the involvement
of ActVA-ORF6 in C-6 oxygenation.
Two other complete biosynthetic gene clusters for the BIQs
(Figures 1B and 1C) have been cloned and sequenced to date:
granaticin (GRA) 4 (the gra cluster) (Sherman et al., 1989; Becht-
hold et al., 1995: Ichinose et al., 1998a) andmedermycin (MED) 5
(themed cluster) (Ichinose et al., 2003). Comparative analysis of
the three clusters revealed the unexpected lack of an actVA-
ORF6 homolog in the gra andmed clusters, even though oxygen
is found at the C-6 position in both GRA 4 and MED 5. Instead,
they include oxygenase genes (gra-ORF21 and med-ORF7,
respectively) homologous to actVA-ORF5, which was initially
deduced to encode a hydroxylase for the C-8 position (Caballero
et al., 1991) based on its significant similarity (>70%) to pheA
encoding a phenol hydroxylase fromBacillus stearothermophilus
(Kim and Oriel, 1995). Recently, ActVA-ORF5 was reported to
form a two-component monooxygenase together with a flavin:
NADH oxidoreductase, ActVB, which provides reduced flavin
to the actual oxygenase component conducting the C-8 oxygen-
ation in ACT biosynthesis (Valton et al., 2004, 2006). The gra and
med clusters also contain genes homologous to actVB (gra-
ORF34 and med-ORF13, respectively). The absence of the
hydroxyl group at C-8 of MED 5 as well as the lack of an
actVA-ORF6 homolog in the med cluster prompted us to
propose the possible involvement of Med-ORF7, an ActVA-
ORF5 homolog, in C-6 oxygenation in MED biosynthesis (Ichi-
nose et al., 2003). These conflicting situations raise questions
about the in vivo contributions of the ActVA-ORF5/ActVB and
ActVA-ORF6 oxygenases to ACT biosynthesis. This paper
describes a functional analysis of the actVA-ORF5, actVA-
ORF6, and actVB genes based onmolecular genetics, metabolic
analysis, and biochemical characterization, revealing a novelevier Ltd All rights reserved
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Alternative Quinone Formation for ActinorhodinFigure 1. The Overview of BIQ Biosyntheses
(A) The proposed later tailoring steps of the ACT biosynthetic pathway. The numbers are based on the biosynthetic order.
(B) The structures of benzoisochromanequinone (BIQ) antibiotics.
(C) The biosynthetic gene clusters of ACT, granaticin, and medermycin. actVA-ORF6 is shown by a dotted arrow. actVA-ORF5 and its homologs are shown by
filled arrows. The actVB homologs are shown by striped arrows.situation in which alternative pathways are available for the later
tailoring steps of ACT biosynthesis.
RESULTS
actVA-ORF5, but Not actVA-ORF6, Is Essential
for ACT Biosynthesis
To establish the in vivo function of actVA-ORF5 and ORF6, we
constructed deletion mutants for these genes. In the act cluster,
the extreme 30 end of actVA-ORF5 overlaps with the 50 end of
actVA-ORF6, indicative of potential translational coupling. Inac-
tivation of actVA-ORF5 would have polar effects on the down-
stream gene, actVA-ORF6. Therefore, we initially inactivatedChemistry & Biology 16, 226both genes by replacing them with a spectinomycin-strepto-
mycin-resistance (aadA) cassette, resulting in a DactVA-5,6
double mutant (see Figure S1 article online). Correct disruption
of the genes was confirmed by Southern blot analysis
(Figure S1). A strain (M510) wild-type for the ACT pathway
produced ACT 1 and its lactonized derivatives (ACTs): g-actino-
rhodin (g-ACT) 6 and g0-actinorhodin (g0-ACT) 7, as shown in
Figure 2. The DactVA-5,6 mutant did not produce ACTs (1, 6,
and 7) at all. Instead, the mutant accumulated a yellowish-
brown pigment, demonstrating the involvement of actVA-
ORF5 and/or actVA-ORF6 in ACT biosynthesis (Figures 2A
and 2C). Our previous spectral analysis elucidated its structure
as a novel perylenequinone-type shunt product, 7H,16H-perylo–236, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 227
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Alternative Quinone Formation for Actinorhodin[2,1c:8,7-c0]dipyran-7,16-dione,1,3,4,9,11,12-hexahydro-8,15-
dihydroxy-1R,9R-dimethyl-3S, 11S-diacetic acid, which was
designated as actinoperylone (ACPL) 8 (Taguchi et al., 2008).
Blocking oxygenation at C-6 of 6-deoxy-dihydrokalafungin
(DDHK) 9 would result in possible tautomerization to the dihy-
droxynaphthalene derivative, followed by oxidative dimerization
to afford ACPL 8. Therefore, C-6 oxidation of DDHK 9 is
deduced to be compromised in the DactVA-5,6 mutant.
Next, we deleted actVA-ORF6 alone to construct the mutant
DactVA-6 (Figure S1), but no obvious effect of the mutation on
ACT production was detected (9% less production than the
wild-type, WT) (Figures 2A and 2C), indicating a rather limited
contribution of actVA-ORF6 to ACT biosynthesis. In addition,
ectopic expression of actVA-ORF5 alone under the control of
a thiostrepton-inducible promoter, tipAp, in the DactVA-5,6
mutant (the recombinant, DactVA-5,6/actVA-5) restored ACT
production in response to thiostrepton induction (Figure 2B;
Figure S2). In contrast, expression of actVA-ORF6 alone in the
DactVA-5,6 mutant (the recombinant, DactVA-5,6/actVA-6) had
no obvious effect on the metabolic profile (Figure S2). It was
Figure 2. Funcitonal Analysis of actVA-ORF5 and
ORF6
(A) Effect of the actVA deletionmutations on ACT biosynthesis.
Strains were inoculated on R5medium and grown at 30C for
4 days. The reverse side of plates is shown.
(B) Complementation of the DactVA-5,6 mutant. The actVA-
ORF5 gene was expressed by using pIJ8600+actVA5. Strains
were grown on R5 medium at 30C for 3 days, either in
the absence (Thio) or presence (+Thio) of thiostrepton
(10 mg/ml).
(C) HPLC chromatograms of the ACT-relatedmetabolites from
culture medium of the strain M510 and its actVA mutants.
Strains were cultured in R5MS medium, and the ACT-related
metabolites in the culture supernatants were analyzed as
described in Experimental Procedures. Chemical structures
of the relevant compounds are shown on the right side of
the panel.
possible that a presumptive homolog of actVA-
ORF6 exists elsewhere in the genome and
compensated for the mutation. However, genomic
sequence analysis of S. coelicolor A3(2) (Bentley
et al., 2002) revealed no homologs of actVA-
ORF6, at least from the view of amino acid
sequence homology. Furthermore, it has been
demonstrated that the act cluster contains all
genetic information required for ACT biosynthesis
(Malpartida and Hopwood, 1984). Apparently,
actVA-ORF5, but not actVA-ORF6, is essential for
ACT biosynthesis, and the C-6 oxygenation step
in ACT biosynthesis should be mainly governed
by actVA-ORF5.
In Vivo Contribution of ActVA-ORF5/ActVB
and ActVA-ORF6 as the C-6Monooxygenase
A flavin:NADH oxidoreductase, ActVB, has been
reported to be necessary for ActVA-ORF5 to
function as amonooxygenase in vitro, and a combi-
nation of the two proteins was named the ActVA-
ActVB system (Valton et al., 2004, 2006). In our study, a more
precise designation, the ActVA-ORF5/ActVB system, is
proposed. To clarify the in vivo function of actVB, this gene
was replaced by an erythromycin-resistance (ermE) cassette
as described in Experimental Procedures (Figure S3). HPLC
analyses of culture supernatants clearly showed that the deletion
mutant, DactVB, produced ACTs (6 and 7) and ACPL 8 simulta-
neously (Figure 3). Quantitative estimations demonstrated that
the total amount of ACTs (6 and 7) produced was decreased to
about 30% of wild-type levels made by M510. The amount of
ACPL 8 was almost the same as in the DactVA-5,6 mutant.
This result indicates that deletion of actVB perturbed the
ActVA-ORF5/ActVB system and led to interruption of efficient
C-6 oxygenation of DDHK 9. Previously, an actVB mutant strain,
B135 (Rudd and Hopwood, 1979), was reported to produce
kalafungin (KAL) 14 (Cole et al., 1987). Under our culture condi-
tions, however, the strain B135 was confirmed to produce g-
ACT 6 and ACPL 8, consistent with the results from our DactVB
mutant, and neither KAL 14 nor dihydrokalafungin (DHK) 10
could be detected (data not shown).228 Chemistry & Biology 16, 226–236, February 27, 2009 ª2009 Elsevier Ltd All rights reserved
Chemistry & Biology
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DactVB mutation should be highly detrimental to the enzymatic
function of the ActVA-ORF5/ActVB system. Nevertheless, the
mutant produced a significant amount of ACTs. Therefore, we
decided to investigate the contribution of actVA-ORF6 in this
genetic background. For this purpose, we constructed a DactVB
DactVA-ORF6 double mutant (DactVBDactVA-6). This mutant
still accumulated ACPL 8 (Figure 3), but virtually no ACTs (1, 6,
and 7), indicating that ActVA-ORF6 really catalyzes C-6 oxygen-
ation, and that this manifestation of enzymatic activity depends
on the DactVB mutation. In other words, C-6 oxygenation is
normally governed by the ActVA-ORF5/ActVB system, and the
ActVA-ORF6 protein contributes as an alternative C-6monooxy-
genase in the actVBmutant background, in which the function of
the highly efficient ActVA-ORF5/ActVB system is compromised.
In Vitro Activity of ActVA-ORF5/ActVB
as a Quinone-Forming Oxygenase
The results described above strongly suggest that the ActVA-
ORF5/ActVB system is a quinone-forming enzyme that converts
DDHK 9 into DHK 10. To demonstrate this enzymatic activity
in vitro, we expressed and purified both ActVA-ORF5 and ActVB
as His6-tagged proteins (Figure S4). We also prepared His6-
tagged ActVA-ORF6 as a positive control. Because the
presumptive natural substrate, DDHK 9, is not available, we
used emodinanthrone 11 as a model substrate (Figure 4). This
compound was successfully used in previous studies of other
quinone-forming enzymes (Chen et al., 1995), and its chemical
structure ismore analogous to that of DDHK 9 than tetracenomy-
cin F1 (TCMF1) 13, which was used in the biochemical studies of
ActVA-ORF6 (Kendrew et al., 1997). ActVA-ORF5 and ActVB
proteins were incubated with emodinanthrone 11 and cofactors
FMN and NADH as described in Experimental Procedures. Strik-
ingly, the reconstituted ActVA-ORF5/ActVB system catalyzed
Figure 3. Effect of the DactVB and DactVB DactVA-ORF6 Double
Mutations on ACT Biosynthesis
HPLC profiles monitored by absorbance at 450 nm are shown. The DactVB
mutant produced ACTs (6 and 7) and ACPL 8 simultaneously, whereas the
DactVB DactVA-ORF6 double mutant produced only ACPL 8.
Figure 4. Demonstration of an In Vitro Quinone-
Forming Monooxygenase Activity of the ActVA-
ORF5/ActVB System
(A) HPLC analysis of reaction products. ActVA-ORF5
(1 mM) and ActVB (100 nM) were incubated with emodin-
anthrone 11 (50 mM) for 10 min at 25C as described in
Experimental Procedures. Elution profiles were monitored
by absorbance at 254 nm. Top, authentic (0.5 mg each)
emodinanthrone 11 and emodin 12; bottom, an ethyl
acetate extract from an in vitro assay mixture.
(B) Mass spectra of emodinanthrone 11 and emodin 12
extracted from a reaction mixture. The peaks correspond-
ing to emodinanthrone 11 (m/z 255 as [M-H]) and emodin
12 (m/z 269 as [M-H]) were detected.
(C) Kinetic properties of ActVA-ORF5/ActVB, ActVA-
ORF6, and their related enzymes.Chemistry & Biology 16, 226–236, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 229
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a quinone-forming activity of the system (Figures 4A and 4B).
We confirmed, as shown by Valton et al. (2004, 2006), that
ActVA-ORF5, the genuine oxygenase component, absolutely
required ActVB, FMN, and NADH for its enzymatic activity
(data not shown). In contrast, ActVA-ORF6 did not require any
exogenously added cofactors, as described previously (Ken-
drew et al., 1997).
To characterize the enzymatic properties of the ActVA-ORF5/
ActVB system, kinetic parameters were determined (Figure 4C).
Interestingly, the Km for emodinanthrone 11 of this enzyme
system was significantly lower than that of ActVA-ORF6
(7.54 mM versus 211 mM) and comparable to that of AknX,
a distant homolog of ActVA-ORF6 involved in aklavinone biosyn-
thesis in Streptomyces galilaeus (Chung et al., 2002). These
results imply more efficient oxidation of DDHK 9 by the ActVA-
ORF5/ActVB system. Together, we unambiguously demon-
strated an enzymatic activity of ActVA-ORF5/ActVB as
a quinone-forming oxygenase.
An Additional Oxygenase Activity of the ActVA-ORF5/
ActVB System
The ActVA-ORF5/ActVB system has been proposed to be
involved in the C-8 hydroxylation step in ACT biosynthesis
(Valton et al., 2006, 2008). Therefore, we then investigated this
possibility. Our model substrate emodinanthrone 11 is suitable
to detect a quinone-forming activity because of its intrinsic
slow rate of autoxidation. However, this compound 12 is unlikely
to be hydroxylated at position 4 (equivalent to C-8 of ACT), owing
to its highly substituted nature. Thus, we used less substituted
anthracenes, anthrone, and dithranol to detect quinone forma-
tion and subsequent hydroxylation. These model substrates
were assessed under our standard assay conditions as
Figure 5. Demonstration of a DHK Oxygen-
ation Activity of the ActVA-ORF5/ActVB
System
(A) HPLC analysis of reaction products. Assay
conditions were essentially the same as those
used for emodinanthrone 11 (Figure 4). Top, DHK
10 (50 mM) was incubated with ActVA-ORF5 and
ActVB; bottom, DHK without the enzymes.
(B) Mass spectra of (X), KAL 14, and (Y) extracted
from a reaction mixture. The peaks corresponding
to X, Y (m/z 315 as [M-H]), and KAL 14 (m/z 299
as [M-H]) were detected.
described in Experimental Procedures.
Although these compounds were rapidly
converted to their cognate quinone form
by autoxidation, the ActVA-ORF5/ActVB
system significantly enhanced this rate,
confirming a quinone-forming activity of
the enzyme system (Figure S5). However,
no hydroxylation activity was detected in
these assays (Figure S5).
Finally, therefore, we decided to use
the presumptive natural substrate, DHK
10, for C-8 hydroxylation to assess the
involvement of the ActVA-ORF5/ActVB system in this biosyn-
thetic step. Results of assays are shown in Figure 5. DHK 10 is
spontaneously lactonized, possibly via a hydroquinone form, to
KAL 14 (Ichinose et al., 1998b), which was detected irrespective
of the presence of the enzyme system (Figure 5A). Strikingly, the
reaction with the enzyme system provided new compounds
X and Y (Figure 5A), and their molecular mass was shown to
be 315 (ESI-negative) (Figure 5B), implying that these
compounds are oxygenated molecules of KAL 14. It is likely
that these compounds are generated by C-8 or C-10 hydroxyl-
ation catalyzed by the ActVA-ORF5/ActVB monooxygenase
system. Based on the significant decrease of KAL 14 in the enzy-
matic sample, this compound is suggested to be the actual
substrate for oxygenation to produce the compounds X and Y.
Although further structural elucidation is required, we clearly
demonstrated that the ActVA-ORF5/ActVB system possesses
an additional oxygenation activity other than the quinone-form-
ing activity we discovered.
Shunt Pathway Leading to 8 in Relation
to C-6 Oxygenation
A proposed scheme (Taguchi et al., 2008) for the formation of
ACPL 8 includes oxidative coupling of DDHK 9, which is the
postulated product of a reductase, ActVI-ORF2 (Taguchi et al.,
2000) (Figure 7). To elucidate the essential genes for the shunt
pathway to ACPL 8, we analyzed the act cluster-deficient strain,
CH999, carrying plasmid-borne copies of the act biosynthetic
genes required for the formation of (S)-DNPA 3, with actVI-
ORF2 in addition (CH999/pIJ5659) (Ichinose et al., 1999).
HPLC analysis of a liquid culture of CH999/pIJ5659 clearly de-
tected ACPL 8 (Figure 6). This result proves that actVI-ORF2
indeed encodes a reductase for C-15, and, most importantly,
formation of ACPL 8 was demonstrated by the minimal gene230 Chemistry & Biology 16, 226–236, February 27, 2009 ª2009 Elsevier Ltd All rights reserved
Chemistry & Biology
Alternative Quinone Formation for Actinorhodinsets for the possible formation of DDHK 9. Interruption of the C-6
oxygenation of DDHK 9 would result in possible tautomerization
to the dihydroxynaphthalene derivative, followed by oxidative
dimerization to afford ACPL 8. One of the possible candidates
involved in the coupling is a P450 gene (Zhao et al., 2007) outside
the act cluster.
DISCUSSION
Oxidative modifications catalyzed by monooxygenases are
common tailoring steps in the biosynthesis of polyketide metab-
olites, including both aromatic and macrocyclic antibiotics. The
most extensively studied examples are the cytochrome P450-
dependent monooxygenases (Munro et al., 2007). However,
the 22 kb act biosynthetic gene cluster carries no genes for
P450-type enzymes, suggesting that distinct kinds of monooxy-
genases are involved in the oxygenation steps at C-6 and C-8 in
ACT biosynthesis.
ActVA-ORF6 significantly resembles the monooxygenase
encoded by tcmH involved in tetracenomycin (TCM) biosyn-
thesis in Streptomyces glaucescens (Shen and Hutchinson,
1993). Because TcmH had been shown to be a quinone-forming
monooxygenase that converts TCMF1 13 to TCMD3, it was
Figure 6. Formation of Actinoperylone by the Minimal Gene Set
HPLC analyses of metabolites produced by S. coelicolorCH999 recombinants
harboring either pIJ5660 or pIJ5659. Chromatograms monitored by absor-
bance at 450 nm are shown. The gene sets used for the plasmids are also
shown above each chromatogram. The recombinant strain harboring
pIJ5660 produced (S)-DNPA 3. On the other hand, the strain harboring
pIJ5659 accumulated a shunt product, ACPL 8.Chemistry & Biology 16, 226reasonable to assume that ActVA-ORF6 catalyzes the C-6
oxygenation of DDHK 9 (Ferna´ndez-Moreno et al., 1994). Indeed,
Kendrew et al. (1997) demonstrated its quinone-forming activity
by using TCMF1 13 as a model substrate. Furthermore, the
crystal structure of ActVA-ORF6 in complex with substrate and
product analogs provided an explanation for C-6 oxygenation,
where the active site cavity of the enzyme acts as a shield for
the substrate, DDHK 9, leaving only the C-6 carbon exposed
to molecular oxygen (Sciara et al., 2003).
Although C-6 oxygenation is a tailoring step common to all BIQ
biosyntheses, neither the gra normed cluster possesses actVA-
ORF6 homologs (Figure 1C). This prompted us to investigate the
in vivo contribution of actVA-ORF6 to ACT production. An actVA-
ORF6 deletion mutant produced ACTs at levels only slightly less
than the wild-type, suggesting a rather limited contribution of the
gene to ACT biosynthesis (Figure 2). Instead, the gene immedi-
ately upstream, actVA-ORF5, was found to be critical for C-6
oxygenation in the present study (Figures 2 and 4). The actVA
genetic region corresponds to one of the phenotypic classes
of blocked mutants that produce diffusible brown pigments
(Rudd and Hopwood, 1979). Most of the actVA mutations were
mapped to the actVA-ORF5 gene (Caballero et al., 1991), and
later chemical characterization of an actVA-ORF5 mutant (strain
B1) carrying the act-101 mutation (Caballero et al., 1991) identi-
fied (S)-DNPA 3 as an actVA intermediate (Cole et al., 1987). We
also analyzed the same class of actVA-ORF5 mutant (strain B9)
carrying the act-109 mutation (Caballero et al., 1991) and identi-
fied ACPL 8 as a major ACT-related metabolite, but a trace
amount of (S)-DNPA 3, though no ACTs (1, 6, and 7), was also
detected (data not shown). These results demonstrated the
critical role of actVA-ORF5 in C-6 oxygenation. Consistent with
this conclusion, the gra and med clusters carry homologs of
actVA-ORF5, gra-ORF21 (Ichinose et al., 1998a), and med-
ORF7 (Ichinose et al., 2003).
The actVB gene was initially identified genetically among actV
mutants, being phenotypically similar but not identical to the
actVA mutants (Rudd and Hopwood, 1979; Ferna´ndez-Moreno
et al., 1992). Based on the isolation of KAL 14, which is
convertible in vivo to ACT 1 (Cole et al., 1987), actVB had been
postulated to be involved in oxidative dimerization in ACT
biosynthesis. Despite an apparent lack of an equivalent biosyn-
thetic step, we discovered actVB homologs (gra-ORF34, med-
ORF13) in the other BIQ gene clusters (Ichinose et al., 1998a,
2003) (Figure 1C), indicating their role in a step common to the
biosynthesis of these undimerized compounds. The ActVB
protein was shown to be a flavin:NADH oxidoreductase (Ken-
drew et al., 1995). Recently, the ActVA-ORF5 and ActVB proteins
were reported to constitute a two-component monooxygenase
system, in which ActVB donates reduced flavin to the actual oxy-
genase component, ActVA-ORF5 (Valton et al., 2004), providing
an explanation for the copresence of their cognate genes in all
BIQ pathways. Detailed biochemical studies (Valton et al.,
2008) proposed the involvement of the ActVA-ORF5/ActVB
system in the oxygenation step at C-8 in ACT biosynthesis.
However, notwithstanding the absence of the hydroxyl group
at C-8 in MED 5, highly conserved orthologs of actVA-ORF5
(med-ORF7) and actVB (med-ORF13) are present in the med
gene cluster. This fact implies an additional function for the
ActVA-ORF5/ActVB system other than as a catalyst for C-8–236, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 231
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The ACT biosynthetic pathway exploits a dual enzyme system for the C-6 oxygenation of DDHK 9. The ActVA-ORF5/ActVB system is a principal enzyme for this
reaction. The ActVA-ORF6 protein also catalyzes the same reaction, but its contribution is rather limited in the wild-type genetic background. However, the
activity of ActVA-ORF6 is manifested in the actVB genetic backgrounds. Production of ACT 1 from DHK 10 requires at least two reaction steps: dimerization
and 8-hydroxylation.hydroxylation. Indeed, we demonstrated the involvement of
ActVA-ORF5/ActVB in the C-6 oxygenation step.
We further investigated the in vivo contributions of the ActVA-
ORF5/ActVB and ActVA-ORF6 monooxygenases by construct-
ing an actVB deletion mutant (DactVB). This mutant was
expected to produce ACPL 8, owing to a lack of the principal
C-6 monooxygenase, AtctVA-ORF5/ActVB. In fact, the DactVB
mutant accumulated ACPL 8 (Figure 3), but still produced
a considerable amount of ACTs (6 and 7), indicating two possibil-
ities: (i) ActVA-ORF5 itself is partially functional without ActVB; (ii)
ActVA-ORF6 makes a significant contribution in the DactVB
genetic background. To clarify this issue, we then prepared an
actVB actVA-ORF6 double mutant (DactVBDactVA-6), and we
confirmed that ACT production was virtually abolished in this
mutant, although the accumulation of ACPL 8 was still observed
(Figure 3). The results clearly indicate that ActVA-ORF6 is also
functional in vivo and that its activity as a C-6 monooxygenase
is manifested in the actVB mutant, in which the function of the
ActVA-ORF5/ActVB system is compromised.
Following the in vivo experiments, we attempted to prove an
in vitro quinone-forming activity of the ActVA-ORF5/ActVB
system. We could readily reconstitute the two-component
system with purified recombinant proteins and detect its enzy-
matic activity by using emodinanthrone 11 as a model substrate
(Figure 4). A quinone-forming activity of the ActVA-ORF6 protein
was also confirmed in our assay system. These observations
reinforce our claim that the ActVA-ORF5/ActVB system is the
principal C-6 monooxygenase in ACT biosynthesis.
It is interesting that ActVA-ORF6 has a lower Km for tetraceno-
mycin F1 (TCMF1) 13 than for a substrate closer in structure to an
ACT intermediate, and that it is present only in the ACT system,232 Chemistry & Biology 16, 226–236, February 27, 2009 ª2009 Elseven though GRA and MED biosynthesis also requires C-6
oxygenation. Perhaps the actVA-ORF6 gene has been acquired
by horizontal gene transfer from an unknown source, now
providing an alternative route to C-6 oxygenation.
An immediate interestwould be thepossible involvement of the
ActVA-ORF5/ActVB systemnot only in C-6 oxygenation, but also
in C-8 hydroxylaton, as proposed previously (Valton et al., 2006,
2008). Under our assay conditions, the model anthrone
substrates (emodinanthrone 11, anthrone, and dithranol) were
efficiently converted to the corresponding anthraquinones, but
they did not receive any additional oxygenation. Therefore, we
used the presumptive natural substrate, DHK 10. As expected,
this compound was readily converted to the oxygenated
compounds (Figure 5), which possess the molecular mass (316)
corresponding to hydroxylated KAL 14. Previous studies on the
ActVA-ORF5/ActVB system (Valton et al., 2006) demonstrated
its in vitro oxygenating activity that catalyzes the conversion of
DHK 10 to its monooxygenated derivative, DHK-OH, with
amolecularmass of 318. This conversionwas, however, less effi-
cient, and the true substrate was suggested to be the hydroqui-
none form of DHK 10, which was efficiently oxygenated under
the anaerobic assay conditions employed (Valton et al., 2006).
Our experimental data imply that KAL 14, but not DHK 10, is
the actual substrate for this enzymatic reaction (Figure 5).
Although further studies are required to determine the bona fide
biosynthetic substrate for the hydroxylation reaction and the
chemical structure of the reaction products, we demonstrated
unambiguously an additional oxygenation activity other than
the quinone-forming activity of the ActVA-ORF5/ActVB system.
The shunt formation of ACPL 8 by the actVA-ORF5 or actVB
mutants is reasonably explained by oxidative coupling ofevier Ltd All rights reserved
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the recombinant strain with the expression plasmid (pIJ5659)
carrying the minimal set of genes for the formation of DDHK 9
produced ACPL 8, clearly suggesting a direct link between inter-
ruption of C-6 oxygenation and oxidative coupling.
The combined data allow us to propose an alternative oxygen-
ation pathway in ACT biosynthesis as shown in Figure 7,
including a dual C-6 oxygenation system consisting of ActVA-
ORF5/ActVB and ActVA-ORF6. Our experimental results do
not disprove the functional assignment of the ActVA-ORF5/
ActVB system as a C-8 hydroxylase. Neither the missense
actVA-ORF5 mutant (strain B9; unpublished data) nor the
DactVA-5,6 mutant harboring the actVA-ORF6 expression
plasmid produced any ACTs (1, 6, and 7), although the alterna-
tive C-6 monooxygenase ActVA-ORF6 is highly likely to be func-
tional in these strains. Thus, it is apparent that the ActVA-ORF5
protein is involved in an additional biosynthetic step after C-6
oxygenation. Indeed, we confirmed an additional function of
the ActVA-ORF5/ActVB system other than that as a quinone-
forming enzyme. Further genetic and chemical studies are in
progress to elucidate details of the late ACT biosynthetic
pathway, including the C-8 hydroxylation step.
SIGNIFICANCE
The striking conclusion from this work is that the gene
cluster for ACT biosynthesis encodes two alternative routes
for quinone formation at a critical stage in post-PKS
tailoring. One of these, catalyzed by ActVA-ORF5/ActVB, is
the major route in the wild-type, but when actVB is deleted
(and perhaps when the expression level of actVB is low in
the wild-type), the alternative route, catalyzed by ActVA-
ORF6, becomes manifested. Oxygenation, including
quinone formation and hydroxylation, is one of the key steps
in secondary metabolism; thus, these findings may have
wide significance for understanding and manipulating the
oxygenation of a variety of aromatic compounds. The
possible bifunctionality of the ActVA-ORF5/ActVB system
found in this study would open the possibility of its applica-
tion to the oxygenation of various aromatic compounds.
EXPERIMENTAL PROCEDURES
Bacterial Strains
S. coelicolor M510 (M145 DredD) (Floriano and Bibb, 1996) was used as the
wild-type strain throughout this study. This strain does not produce the red-
pigmented prodiginines due to the DredD mutation, allowing for easy charac-
terization of actmutants.S. coelicolorCH999 (proA1 argA1 redE60Dact::ermE
SCP1 SCP2) (McDaniel et al., 1993) was also used in some experiments.
Streptomyces lividans TK21, Escherichia coli DH5a, and E. coli GM2163
(dam dcm) were used for routine DNA manipulation. E. coli BL21(DE3)/
pLysS was used as the host for protein expression. Streptomyces tanashiensis
JCM4086 (RIKEN) was used for the isolation of DHK.
DNA Manipulation
Plasmid isolation, restriction enzyme digestion, ligation, and transformation of
E. coli and Streptomyces were performed as described previously (Kieser
et al., 2000; Sambrook et al., 1989). PCRwas performed with LA Taq (TaKaRa,
Japan) or KOD -Plus- (Toyobo, Japan) DNA polymerase. PCR primers used in
this study are listed in Table S1.Chemistry & Biology 16, 226Construction of the DactVA-5,6, DactVA-6, and DactVB Mutants
The DactVA-5,6 Mutant
A 1 kb region 50 of actVA-ORF5 was amplified by PCR with primers DactVA5,
6-UF and DactVA5,6-UR. A second 1.1 kb region 30 of actVA-ORF6was ampli-
fied with primers DactVA6-DF and DactVA6-DR. The PCR fragments were
inserted between the EcoRI and HindIII sites of pUC19 by three-fragment liga-
tion, yielding pUC19+DactVA5,6. The aadA gene was amplified from pIJ2059
(Kieser et al., 2000) by using primers aadA-F and aadA-R. The amplified aadA
gene cassette was cloned in the XbaI site of pUC19+DactVA5,6, generating
pUC19+DactVA5,6::aadA. The DactVA5,6::aadA construct was excised by
digestion with EcoRI and HindIII and was ligated with pGM9 (Kieser et al.,
2000), which had been treated with the same enzymes. The ligation mixture
was used to transform S. lividans TK21 protoplasts to yield the plasmid
pGM9+DactVA5,6::aadA. S. coelicolor M510 was transformed with
pGM9+DactVA5,6::aadA, and transformants were selected with thiostrepton
(Thio). To obtain single-crossover recombinants, purified transformants were
cultured on Thio-containing plates at 37C. Because pGM9 carries a tempera-
ture-sensitive replicon of pSG5, it cannot replicate at this temperature. Thio-
resistant single-crossover recombinants were subcultured by two rounds of
streaking in the absence of Thio at 37C. Double-crossover recombinants
(DactVA-5,6) in which the delivery plasmid was lost from cells were identified
as colonies with Thio-sensitive and streptomycin-resistant phenotypes.
The correct deletion of the genes was confirmed by PCR and Southern blot
analyses.
The DactVA-6 Mutant
A1kb region 50 of actVA-ORF6wasamplifiedbyPCRwithprimersDactVA6-UF
andDactVA6-UR. A 1.1 kb region 30 of actVA-ORF6was amplified asdescribed
above. These PCR fragments were inserted between the EcoRI and HindIII
sites of pUC19 by three-fragment ligation, generating pUC19+DactVA6. The
aadA gene cassette described above was cloned in this recombinant plasmid,
yielding pUC19+DactVA6::aadA. The DactVA6::aadA construct was excised
by digestion with EcoRI and HindIII and ligated with pGM9 to obtain
pGM9+DactVA6::aadA. The resultingplasmidwas introduced intoS.coelicolor
M510, and the actVA-ORF6 deletion mutant (DactVA-6) was obtained as
described above.
The DactVB Mutant
A 1 kb region 50 of actVB was amplified with primers DactVB-UF and DactVB-
UR. A second 1 kb region 30 of actVB was amplified with primers DactVB-DF
and DactVB-DR. The PCR fragments were inserted between the EcoRI and
XhoI sites of pGEM-11zf by three-fragment ligation, yielding pGEM+DactVB.
The erythromycin/lincomycin-resistance gene, ermE, was excised from
pIJ4026 (Kieser et al., 2000) by digestion with KpnI and was ligated with
pGEM+DactVB, which had been treated with the same enzyme, generating
pGEM+DactVB::ermE. The DactVB::ermE construct was recovered by diges-
tion with EcoRI and XhoI and ligated with pGM9 to obtain pGM+DactV
B::ermE. This plasmid was introduced into S. coelicolorM510, and the actVB
deletion mutant (DactVB) was screened by virtue of Thio-sensitive and linco-
mycin-resistance phenotypes. Similarly, pGM+DactVB::ermE was introduced
into the DactVA6 mutant, and the DactVB DactVA-ORF6 double mutant
(DactVBDactVA6) was obtained in analogous fashion.
Southern Hybridization
DNA fragments from agarose gels were transferred to Hybond-N+ nylon
membrane (GE Healthcare). Probes were prepared by PCR with the following
primer sets: actVA5,6 probe, DactVA5,6-Pro-F, and DactVA5,6-Pro-R; aadA
probe, aadA-F, and aadA-R; actVB probe, DactVB-Pro-F, and DactVB-Pro-
R; ermE probe, ermE-F, and ermE-R. These probes were nonradioactivlely
labeled by using the DIG DNA labeling kit (Roche). Hybridization, washing,
and detection were performed as recommended by themanufacturer (Roche).
Plasmids
The plasmids used for complementation of the DactVA-5,6 mutant were con-
structed as follows. The actVA-ORF5 gene was amplified with the primers
actVA5-Nde and actVA5-Bam. The NdeI-BamHI fragment was inserted
into the Streptomyces expression plasmid pIJ8600 (Kieser et al., 2000) that
has the Thio-inducible tipA promoter, generating pIJ8600+actVA5. Similarly,
the actVA-ORF6 gene was amplified with the primers actVA6-Nde and–236, February 27, 2009 ª2009 Elsevier Ltd All rights reserved 233
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cloned into pIJ8600, yielding pIJ8600+actVA6.
The E. coli expression plasmids used for purification of recombinant
proteins were constructed as follows. The actVA-ORF5 gene was excised
from pIJ8600+actVA5 as the NdeI-BamHI fragment and cloned into pET-
19b. The resulting plasmid, pET-actVA5, attaches the N-terminal His-tag
sequence. Plasmid pET-actVA6 was constructed by using the DNA fragment
amplified with primers actVA6-Nde and actVA6-Xho. The NdeI-XhoI fragment
was inserted into pET-22b. The resulting plasmid, pET-actVA6, attaches the
C-terminal His-tag sequence. The actVB gene was amplified with primers
actVB-Nde and actVB-Bam, and the PCR fragment was cloned into pET-
19b, yielding pET-actVB.
Culture Conditions for Production of ACT-Related Metabolites
Seed cultures (10 ml) were grown in TSB medium (Kieser et al., 2000) on
a rotary shaker at 220 rpm and 30C for 2 days. An aliquot (2 ml) of the seed
culture was inoculated to 50 ml R5MS medium (consisting of 10 g/l glucose,
5 g/l yeast extract [Difco], 0.1 g/l casamino acids, 0.25 g/l K2SO4, 10.12 g/l
MgCl2$6H2O, 5.73 g/l TES buffer, 2 ml/l trace element solution [pH 7.2]) in
a 500 ml Erlenmyer flask, and the culture was grown with shaking (220 rpm)
at 30C for 4 days. R5 medium (Huang et al., 2001) was used for solid
cultures.
HPLC Analysis
An aliquot of culture (1 ml) was centrifuged at 13,2003 g for 5 min. The super-
natant (100 ml) was directly subjected to reversed-phase HPLC analysis on
a Waters Multisolvent System under the following conditions: column, TSK
gel ODS-100V (4.6 id 3 150 mm, TOSOH); column temperature, 40C;
gradient elution, solvent A (0.5% acetic acid in CH3CN) and solvent B
(0.5% acetic acid in deionized H2O); gradient profile: 0–35 min, 10%–94%
A; 35–40 min, 94% A; 40–45 min, 94%–10% A; flow rate, 1.0 ml/min; detec-
tion, absorption between 250 and 600 nm using a photo-diode array detector
(Waters 2996, Waters).
Expression and Purification of Recombinant ActVA-ORF5,
ActVA-ORF6, and ActVB Proteins
His-ActVA-ORF5
E. coli BL21(DE3)/pLysS harboring pET-actVA5 was grown at 37C to an
OD600 of 0.7 in 100 ml LB medium containing 0.2% glucose, 50 mg/ml ampi-
cillin, and 25 mg/ml chloramphenicol (LBGAC). Expression was induced with
1 mM isopropyl-b-D-thiogalactopyranoside (IPTG), and incubation was
continued at 37C for an additional 3 hr. Cells were collected by centrifugation
and stored at 70C. The cell pellet was resuspended in buffer A (20 mM
sodium phosphate [pH 7.4], 500 mM NaCl, 100 mM imidazole, 2 mM dithio-
threitol, 0.1%CHAPS) containing Complete protease inhibitor cocktail (Roche)
and sonicated. Insoluble material was removed by centrifugation, and the
crude cell extract was chromatographed on a 1 ml HisTrap HP column (GE
Healthcare) equilibrated with buffer A. Then, the column was washed with
buffer A containing 300 mM imidazole, and the His-ActVA-ORF5 protein was
eluted with 500 mM imidazole in the same buffer. The fractions containing
His-ActVA-ORF5 were pooled and dialyzed against a buffer containing
20 mM Tris-HCl (pH 7.5), 2 mM dithiothreitol, 0.1% CHAPS, and 10% (w/v)
glycerol. Protein concentration was determined by the Bradford procedure.
Aliquots of the purified protein were stored at 70C.
ActVA-ORF6-His
E. coli BL21(DE3)/pLysS transformed with pET-actVA6 was grown at 37C to
an OD600 of 0.7 in 100 ml LBGACmedium. Expression was induced with 1 mM
IPTG, and incubationwas continued at 37C for an additional 3.5 hr. Cells were
harvested by centrifugation and stored at 70C. The cell pellet was resus-
pended in buffer B (20 mM sodium phosphate [pH 7.4], 500 mM NaCl,
20mM imidazole, 1mMdithiothreitol, 10% (w/v) glycerol) containingComplete
protease inhibitor cocktail and sonicated. After centrifugation, the crude cell
extract was chromatographed on a 1 ml HisTrap HP column equilibrated
with buffer B. Then, the column was washed with buffer B containing
100 mM imidazole, and the ActVA-ORF6-His protein was eluted with
300 mM imidazole in the same buffer. The fractions containing ActVA-ORF6-
His were pooled and dialyzed against a buffer containing 20 mM Tris-HCl234 Chemistry & Biology 16, 226–236, February 27, 2009 ª2009 Els(pH 7.5), 1 mM dithiothreitol, and 20% (w/v) glycerol. Aliquots of the purified
protein were stored at 70C.
His-ActVB
E. coli BL21(DE3)/pLysS harboring pET-actVB was grown at 37C to an OD600
of 0.3 in 100 ml LBGAC medium. Expression was induced with 250 mM IPTG.
To minimize the formation of inclusion bodies, the culture was cooled to 25C
after the addition of IPTG and then further grown for 5 hr at this temperature.
Cells were collected by centrifugation and were stored at 70C. The cell
pellet was resuspended in buffer C (20 mM sodium phosphate [pH 7.4],
500 mM NaCl, 100 mM imidazole, 2 mM dithiothreitol, 0.1% CHAPS, 10%
(w/v) glycerol) containing Complete protease inhibitor cocktail and sonicated.
After centrifugation, the crude cell extract was loaded onto a 1 ml HisTrap HP
column equilibrated with buffer C. Then, the column was washed with buffer C
containing 300 mM imidazole, and the His-ActVB protein was eluted with 500
mM imidazole in the same buffer. The fractions containing His-ActVB were
pooled and dialyzed against a buffer containing 25 mM Tris-HCl (pH 7.5),
0.1% CHAPS, and 10% (w/v) glycerol. Aliquots of the purified protein were
stored at 70C.
Substrates for In Vitro Enzyme Assay
Anthrone and dithranol were purchased from Aldrich and SIGMA, respec-
tively. Anthraquinone (Wako Pure Chemical Industries, Ltd.) and chrysazin
(Tokyo Chemical Industry Co., Ltd.) were also purchased for the authenticity
of the reaction products. Emodinanthrone 11 was prepared by reduction of
emodin 12 (SIGMA) by using excess hydrogen iodide (55%) in glacial acetic
acid under reflux for 3 hr as previously described (Chen et al., 1995).
HR-ESIMS data of the resultant emodinanthrone: m/z [M-H] 255.0662
(calculated for C15H11O4, 255.0657). DHK 10 was extracted from liquid culture
of S. tanashiensis JCM4086 (Johnson and Dietz, 1968) and purified. S. tana-
shiensis was cultured in R5MS medium under the same conditions as those
used for S. coelicolor in this work. The crude extract obtained with ethyl
acetate was purified by silica gel column chromatography eluting chloro-
form/ethyl acetate/acetic acid (80:20:1) and preparative HPLC by using
a Waters Multisolvent System under the following conditions: column, TSK
gel ODS-100S (7.8 id 3 300 mm, TOSOH); column temperature, 40C;
solvent, 45% aq. CH3CN containing 0.5% acetic acid (isocratic); flow rate,
2.0 ml/min.
In Vitro Enzyme Assay
Quinone-forming activity was measured spectrophotometrically by following
the increase of absorbance at 490 nm resulting from the formation of emodin
from emodinanthrone at 25C (Chen et al., 1995). Conversion of emodin-
anthrone to emodin also occurs nonenzymatically, especially under alkaline
conditions. Under our assay conditions (pH 7.0), however, the contribution
of the nonenzymatic conversion was slight and always less than 10% of that
of the enzymatic conversion. The assay mixture (500 ml) for the ActVA-
ORF5/ActVB system contained 500 mM NADH, 5 mM FMN, 30% (v/v) ethylene
glycol monomethyl ether, 120 U/ml catalase, 100 nM His-ActVB, 1 mM His-
ActVA-ORF5, and various amounts of emodinanthrone in 25 mM PIPES-
NaOH (pH 7.0). Emodinanthrone in ethyleneglycol monomethylether was
subjected to an assay. The assay mixture (500 ml) for ActVA-ORF6 contained
2 mM ActVA-ORF6-His, 30% (v/v) ethyleneglycol monomethylether, and
various amounts of the substrate in 25 mM PIPES-NaOH (pH 7.0). The enzy-
matic conversion of emodinanthrone to emodin was also confirmed by
LC/ESIMS analysis. A typical analytical sample was prepared from the fore-
going assay mixture as follows. The mixture was extracted with ethyl acetate
(500 ml) followed by evaporation to dryness. The residue was dissolved
in acetone (100 ml), and an aliquot of the solution (5 ml) was subjected to
LC/ESIMS analysis. LC/ESIMS analysis was carried out on a Waters
AllianceHT equipped with a photo-diode array detector (Waters 2995) under-
the following conditions: column, TSK gel ODS-100S (4.6 id 3 150 mm,
TOSOH); column temperature, 40C; solvent, 45% aq. CH3CN containing
0.5% acetic acid (isocratic); flow rate, 1.0 ml/min; detection, absorbance
between 250 and 600 nm. Mass spectrometry data were obtained under elec-
tron spray ionization (ESI) on a Waters LCT-Premier.
DHK monooxygenase activity was detected by LC/ESIMS analysis as
described above. DHK (50 mM) was reacted with His-ActVA-ORF5 (1 mM)
and His-ActVB (100 nM).evier Ltd All rights reserved
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